Andelyn Biosciences Capacity Update May 2024: Cell & Gene Therapy

With the FDA pushing platform approach as a pathway to enabling more rare disease therapies, they also acknowledge the importance of process parameter adjustments specific to individual transgenes. In this presentation from the May 2024 OPCU event, learn how Andelyn's proven methodology and decades-long AAV database at the core of the AAV Curator™ Platform directly drives speed, maximizes yields, and ensures a high-quality product is delivered and manufactured reliably.